About Us
The Buchholz Lab
Systems biology and genome engineering are at the forefront of transforming our healthcare system. The Department of Medical Systems Biology at the University Cancer Center of TU Dresden integrates functional genomics, high-throughput biology and genome editing to transform precision medicine. Join us in shaping the future of healthcare science!
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Research
Find out more about our research
Publications
Follow the work of our researchers
Members
Your contact to our research group members
News
Get to know the news of our research group
News
New publication on tyrosine-type site-specific recombinases
9. May 2023
Our new paper “Discovery and characterization of novel Cre-type tyrosine site-specific recombinases for advanced genome engineering” in collaboration with DKMS Life Science Lab has just been…
Frank Buchholz participating in open discussion on genetic research
21. April 2023
Is there a gene for a bigger and more efficient brain? Can genome surgery soon free us from all diseases? Do my genes determine my character? During audience discussions, experts exchange views on…
The TU Dresden Spin-off Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases in Dresden
16. March 2023
Seed round co-led by Wellington Partners and Forbion, with additional non-dilutive financial support from the BMBF (GO-Bio funding) enables maturation of the proprietary platform and pipeline…